The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Epithelial ovarian cancer remains a significant health challenge.
• Identifying novel therapeutic targets is crucial for improving patient outcomes.
• The Transforming Growth Factor Beta (TGFβ) signaling pathway is implicated in various cancers.

Purpose of the Study:

• To investigate the role of the TGFβ signaling pathway in epithelial ovarian cancer.
• To evaluate the therapeutic potential of TGFβ pathway inhibition.
• To identify downstream targets of TGFβ involved in ovarian tumor proliferation.

Main Methods:

• Analysis of Smad2 phosphorylation in patient-derived ovarian cancer samples using tissue microarrays (TMA).
• In vivo studies using orthotopic ovarian cancer models in nude mice treated with TGFβ receptor inhibitors (LY2109761).
• Assessment of Insulin Growth Factor (IGF)1 receptor (IGF1R) involvement using pharmacological inhibitors (IMC-A12, linsitinib) and shRNA knockdown.

Main Results:

• High Smad2 phosphorylation was observed in ovarian cancer cells, irrespective of subtype.
• TGFβ receptor inhibition significantly reduced tumor growth and cell proliferation in vivo.
• TGFβ signaling positively regulates IGF1R, which is critical for ovarian tumor cell proliferation.
• Inhibition of IGF1R also suppressed ovarian tumor growth.
• LY2109761's anti-proliferative effect was abolished when IGF1R levels were reduced.

Conclusions:

• The TGFβ signaling pathway promotes ovarian cancer growth by controlling IGF1R signaling.
• Anti-TGFβ inhibitors represent a potential therapeutic strategy for ovarian cancer patients.
• Targeting the TGFβ/IGF1R axis offers a novel approach for ovarian cancer treatment.